1Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease[J]. Am J Kidney Dis,1998,32(5 Suppl 3) :S112-119.
2Schomig M, Eisenhardt A, Ritz E. The microinflammatory state of uremia[J]. Blood Purif, 2000,18(4) : 327-332.
3Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy [J]. Semin Dial, 2002,15(5) : 329-337.
4Kaysen GA. The microinflammatory state in uremia: causes and potential consequences[J]. J Am Soc Nephrol, 2001, 12 (7) : 1549-1557.
5Suzuki Y,Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II [J]. Int J Biochem Cell Biol, 2003, 35 (6) : 881- 900.
6Pereira BJ, Shapiro L, King AJ, et al. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients [J]. Kidfiey Int, 1994,45(3) :890-896.
7Panichi V,Migliori M, de Pietro S, et al. C reactive protein in patients with chronic renal diseases[J]. Ren Fail, 2001,23 (3/ 4) : 551-562.
8Craddock PR, Fehr J, Dalmasso AP, et al. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes[J]. J Clin Invest, 1977,59(5) : 879-888.
9Memoli B, Minutolo R, Bisesti V, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes[J]. Am J Kidney Dis,2002 ,39(2): 1266-273.
10Verthelyi D,Ishii KJ,Gursel M,et al. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs[J]. J Immunol, 2001,166 (4) : 2372-2:377.
5Fasseas P, Brilakis ES, Leybishkis, et al. Association of carotid artery intima-media thickness with complex aortic atherosclerosis in patients with recent stroke. Angiology, 2002, 53:185-189.
6Papagianni A, Kokolina E, Kalovoulos M, et al. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant , 2004, 19: 1258-1263.
7Beddhu S, Pappas LM, Ramkumar N, et al. Malnutrition and Atherosclerosis in Dialysis Patients. J Am Soe Nephrol, 2004,15 : 733-742.
8Foley RN,Parfery PS,Sarnak MJ.Clinical epidemiology of cardiovascular disease in chronic renal failure[J].Am J kidney Dis,1998,32(suppl 3):s112-119.
9Arici M,walls J.End-stage renal disease,atherosclerosis,and cardiovascular mortality:is C-reactive protein the missing link?[J].Kidney Int,2001,59(2):407-414.
10de Filippi C,Wasserman S,Rosanio S,et al.Cardiac troponin T and C-reactive protein for predicting prognosis,coronary atherosclerosis,and cardiomyopathy in patients undergoing long-term hemodialysis[J].JAMA,2003,290(3):353-359.
8Reuter SE,Faull RJ,Ranieri E,et al. Endogenous plasmacarnitine pool composition and response to erythropoietintreatment in chronic haemodialysis patients [ J]. Nephrol Di-al Transplant, 2009,24 (3) :990 -996.
9Debska - Slizien A,Owczarzak A, Kunicka D, et al. Erythro-cyte metabolism and renal anemia in hem odialyzed patientssupplemented with L - carnitine [ J]. Int J Nephrol Urol,2011,3(1) :23 -33.
10Sabry AA. The role of oral L - Carnitine therapy in chronichemodialysis patients [ J]. Saudi J Kidney Dis Transpl,2010,21(3):454-459.
